CanaQuest Medical Corp. (CANQF)
Chart Events
Performance Outlook
| Previous Close | 0.3500 |
| Open | 0.3400 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.3300 - 0.3400 |
| 52 Week Range | 0.0551 - 0.4399 |
| Volume | |
| Avg. Volume | 1,536 |
| Market Cap | 6.645M |
| Beta (5Y Monthly) | 1.74 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2500 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CANQF
Related Research
- CANAQUEST MEDICAL CORPORATIONAnalyst Report: FactSet Research Systems Inc.FactSet provides financial data and portfolio analytics to the global investment community. The company aggregates data from third-party data suppliers, news sources, exchanges, brokerages, and contributors into its workstations. In addition, it provides essential portfolio analytics that companies use to monitor portfolios and address reporting requirements. Buy-side clients account for 82% of FactSet's annual subscription value. In 2015, the company acquired Portware, a provider of trade execution software. In 2017, it acquired BISAM, a risk management and performance measurement provider. In 2022, it completed its purchase of CUSIP Global Services.RatingFair ValueEconomic Moat6 days agoMorningstar
ACCESSWIRENHL Alumni Association partners with CanaQuest and NEEKA Health to Conduct Studies for Anxiety and Quality of Life in former NHL Players
TORONTO, ON / ACCESSWIRE / October 31, 2023 / NHL Alumni Association (NHLAA), NEEKA Health Canada("NEEKA"),and CanaQuest Medical Corp ("CanaQuest") are pleased to announce a transformative study partnership that will investigate the efficacy of Mentanine® ...
- ACCESSWIRE
CANAQUEST Announces Award of European Cannabinoid Patent
CanaQuest Medical Corp ("CanaQuest" or the "Company") (OTC:CANQF), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), is pleased to announce it was awarded a European Cannabinoid Patent, a novel Botanical and Tetrahydrocannabinol ("THC") Formulation for the reduction of cannabis-induced negative neuropsychiatric side-effects.
- ACCESSWIRE
CanaQuest Awarded Best Global Medical Cannabinoid Development Company 2023 by UK-based Global Health & Pharma for their 8th Annual Healthcare and Pharmaceutical Program
CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced that it has been awarded the Best Global Medical Cannabinoid Development Company 2023, in its eighth annual Healthcare and Pharmaceutical Awards by Global Health & Pharma, United Kingdom, a
